Loading...

PE anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_GK1dot5_PE_021706
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 1_GK1dot5_PE_021706
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 2_GK15_PE_CD4_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (solid line) or rat IgG2b, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100407 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100408 200 µg 58€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Palacios-Arreola M, et al. 2017. Sci Rep. 10.1038/s41598-017-10135-1. PubMed
  2. Man SM et al. 2016. Cell. 167(2):382-396 . PubMed
  3. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  4. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  5. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  6. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  7. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  8. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  9. Friess MC, et al. 2022. Cell Rep. 38:110334. PubMed
  10. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  11. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  12. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  13. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  14. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  15. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  16. Willinger T, et al. 2014. J Exp Med. 211:685. PubMed
  17. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  18. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  19. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  20. Zhang L, et al. 2020. Front Oncol. 1.243055556. PubMed
  21. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  22. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  23. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  24. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  25. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  26. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  27. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  28. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  29. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  30. Leech JM, et al. 2020. Cell Host & Microbe. 26(6):795-809.e5.. PubMed
  31. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  32. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  33. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  34. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  35. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  36. Yuan X, et al. 2019. JCI Insight. 4:e124317. PubMed
  37. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  38. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  39. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  40. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  41. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  42. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  43. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  44. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  45. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  46. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  47. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  48. Antunes KH, et al. 2022. Front Immunol. 13:867022. PubMed
  49. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  50. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  51. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  52. Collin R, et al. 2014. J Immunol. 193:3503. PubMed
  53. Karki R, et al. 2020. JCI Insight. 5:00. PubMed
  54. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  55. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  56. Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed
  57. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  58. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  59. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  60. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  61. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  62. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  63. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  64. Lv F, et al. 2022. iScience. 25:103639. PubMed
  65. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  66. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  67. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  68. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  69. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  70. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  71. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  72. Huang YL, et al. 2021. Commun Biol. 4:229. PubMed
  73. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  74. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  75. Yang H, et al. 2022. Nutrients. 14:. PubMed
  76. Yang C, et al. 2013. Proc Natl Acad Sci U S A. 111:109. PubMed
  77. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  78. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  79. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  80. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  81. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  82. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  83. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  84. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  85. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  86. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  87. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  88. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  89. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  90. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  91. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  92. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  93. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  94. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  95. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  96. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  97. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  98. Du J, et al. 2018. AMB Express. 8:158. PubMed
  99. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  100. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  101. Cho K, et al. 2021. iScience. 24:103117. PubMed
  102. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  103. Colombo M, et al. 2022. iScience. 25:105042. PubMed
  104. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
  105. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  106. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  107. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
  108. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  109. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  110. Nakamura Y, et al. 2015. Infect Immun . 83:671. PubMed
  111. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  112. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  113. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  114. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  115. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  116. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  117. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  118. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  119. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  120. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  121. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  122. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  123. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  124. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  125. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  126. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  127. Zhang H, et al. 2009. Invest Ophthalmol Vis Sci. 50:2653. PubMed
  128. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  129. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  130. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  131. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
  132. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  133. Liu Y, et al. 2019. Sci Rep. 9:18970. PubMed
  134. Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed
  135. Chen S, et al. 2022. iScience. 25:105176. PubMed
  136. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  137. Mahlios J, Zhuang Y 2011. Mol Immunol. 49:227. PubMed
  138. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  139. Klose R, et al. 2016. Nat Commun. 7:12528. PubMed
  140. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  141. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  142. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  143. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  144. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  145. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  146. Deliyannis G, et al. 2021. JCI Insight. 6:. PubMed
  147. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  148. Gao P, et al. 2021. Nat Commun. 1194:12. PubMed
  149. Yomogida K, et al. 2013. Biochem Biophys Res Commun. 434:263. PubMed
  150. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  151. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  152. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  153. Li H, et al. 2022. iScience. 25:104481. PubMed
  154. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  155. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  156. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  157. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  158. Kong IY, et al. 2020. Cell Rep. 33:108290. PubMed
  159. Fu W, et al. 2020. J Immunol Res. 8820355:2020. PubMed
  160. Mesin L, et al. 2020. Cell. 180(1):92-106.e11.. PubMed
  161. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  162. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  163. Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed
  164. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  165. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  166. Gawish R, et al. 2022. Elife. 11:. PubMed
  167. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  168. Sun J, et al. 2012. Arterioscler Thromb Vasc Biol. 32:15:00. PubMed
  169. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  170. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  171. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  172. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  173. Lee S, et al. 2021. Autophagy. Online ahead of print. PubMed
  174. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  175. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  176. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
RRID
AB_312692 (BioLegend Cat. No. 100407)
AB_312693 (BioLegend Cat. No. 100408)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD4

  • Biotin anti-mouse CD4

  • FITC anti-mouse CD4

  • PE anti-mouse CD4

  • PE/Cyanine5 anti-mouse CD4

  • Purified anti-mouse CD4

  • PE/Cyanine7 anti-mouse CD4

  • APC/Cyanine7 anti-mouse CD4

  • Alexa Fluor® 647 anti-mouse CD4

  • Alexa Fluor® 488 anti-mouse CD4

  • Pacific Blue™ anti-mouse CD4

  • Alexa Fluor® 700 anti-mouse CD4

  • PerCP anti-mouse CD4

  • PerCP/Cyanine5.5 anti-mouse CD4

  • Brilliant Violet 421™ anti-mouse CD4

  • Ultra-LEAF™ Purified anti-mouse CD4

  • Alexa Fluor® 594 anti-mouse CD4

  • Brilliant Violet 711™ anti-mouse CD4

  • Brilliant Violet 510™ anti-mouse CD4

  • Brilliant Violet 605™ anti-mouse CD4

  • Brilliant Violet 785™ anti-mouse CD4

  • PE/Dazzle™ 594 anti-mouse CD4

  • APC/Fire™ 750 anti-mouse CD4

  • GoInVivo™ Purified anti-mouse CD4

  • Brilliant Violet 750™ anti-mouse CD4

  • Brilliant Violet 650™ anti-mouse CD4

  • Spark Blue™ 550 anti-mouse CD4

  • Spark NIR™ 685 anti-mouse CD4

  • KIRAVIA Blue 520™ anti-mouse CD4

  • PE/Fire™ 640 anti-mouse CD4

  • APC/Fire™ 810 anti-mouse CD4

  • PE/Fire™ 700 anti-mouse CD4

  • Spark Violet™ 538 anti-mouse CD4

  • Spark YG™ 593 anti-mouse CD4

  • Spark Blue™ 574 anti-mouse CD4 Antibody

  • Spark UV™ 387 anti-mouse CD4
ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account